Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk CEO addresses U.S. headwinds after guidance shock
03:03am, Wednesday, 04'th Feb 2026
Novo Nordisk CEO Mike Doustdar discusses the pharma giant's Q4 reporting, uptake of obesity drugs and how he plans to navigate price pressures throughout 2026.
CNBC Daily Open: UBS posts strong earnings while Novo Nordisk's U.S. shares crater on slowing growth
02:48am, Wednesday, 04'th Feb 2026
The xAI and SpaceX merger values the combined company at $1.25 trillion. Nvidia CEO Jensen Huang denies rumors about a rift with OpenAI.
Novo Nordisk initiates 2026 share repurchase programme
02:00am, Wednesday, 04'th Feb 2026
Bagsværd, Denmark, 4 February 2026 –The execution of Novo Nordisk A/S' overall share repurchase programme for 2026 of up to DKK 15 billion will be initiated on 4 February 2026. As part of this, Nov
Novo Nordisk's shock 2026 guidance points to obesity battle heating up
01:42am, Wednesday, 04'th Feb 2026
Danish obesity drug giant Novo Nordisk is set to be punished by investors on Wednesday after it gave a far bleaker-than-expected outlook for 2026 and flagged a tough weight-loss market battle ahead as
Novo Nordisk has published its annual report for 2025
01:30am, Wednesday, 04'th Feb 2026
Bagsværd, Denmark, 4 February 2026 – Today, Novo Nordisk A/S has issued its 2025 annual report. The report is available here: https://www.novonordisk.com/investors/annual-report.html and is attac
Novo Nordisk: Compressing Margins And Collapsing Guidance Confirm Sell Thesis
07:03pm, Tuesday, 03'rd Feb 2026
Novo Nordisk A/S faces a structural margin crisis as oral Wegovy cannibalizes its high-margin injectable business. NVO Q4 2025 results confirm margin contraction: net margin fell 170 bps to 33.1%, wit
Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug Outlook
06:49pm, Tuesday, 03'rd Feb 2026
Expand NYSE: NVO Novo Nordisk Today's Change (-14.75%) $-8.69 Current Price $50.24 Key Data Points Market Cap $199B Day's Range $49.96 - $58.63 52wk Range $43.08 - $93.80 Volume 3.7M Avg Vol 21M Gross
Market Today: Disney picks D'Amaro; PepsiCo trims prices
05:35pm, Tuesday, 03'rd Feb 2026
Guru Stock PicksT Rowe Price Equity Income Fund has made the following transactions:Reduce in MET by 1.04%Sold out in ADBEAdd in REXR by 1.73%New position in CO
Novo Nordisk CEO on 2026 Forecast and GLP-1 Pricing
02:39pm, Tuesday, 03'rd Feb 2026
Novo Nordisk CEO Mike Doustdar discusses the company's updated 2026 sales guidance, forecasting a decline of 5 to 13% at constant exchange rates. Doustdar highlights the strong uptake of Novo Nordisk'
Novo Nordisk Stock Falls As 2026 Outlook Signals Pricing Pressure, Slowing Sales
01:56pm, Tuesday, 03'rd Feb 2026
Novo Nordisk A/S (NYSE: NVO) stock is trading lower on Tuesday after the weight-loss drug maker released its 2026 full-year sales and operating profit outlook.
Novo Nordisk's stock tumbles as drugmaker lays out case for declining sales in 2026
01:43pm, Tuesday, 03'rd Feb 2026
The maker of Ozempic and Wegovy blamed pricing pressures and competition for its downbeat outlook.
Novo Nordisk stock tumbles 15% despite strong earnings: here's what spooked investors
01:37pm, Tuesday, 03'rd Feb 2026
Novo Nordisk stock (NVO) plunged approximately 15% after the Danish pharmaceutical giant posted better-than-expected 2025 results but delivered a weak 2026 outlook. The company reported full-year 2025
Novo Nordisk warns of 2026 sales decline, shares fall
01:31pm, Tuesday, 03'rd Feb 2026
Novo Nordisk (NYSE:NVO) shares fell almost 13% on Tuesday as the Danish drugmaker forecast lower sales and profit growth for 2026, citing reduced prices in the United States and loss of exclusivity fo
Wegovy maker Novo Nordisk appoints Jamey Millar head of its US business
12:37pm, Tuesday, 03'rd Feb 2026
Danish drug maker Novo Nordisk said on Wednesday it had appointed Jamey Millar head of its U.S. business, and Hong Chow head of product and portfolio strategy.
Wegovy Maker Novo Nordisk Forecasts Sales Decline in 2026
12:18pm, Tuesday, 03'rd Feb 2026
The Danish drugmaker said adjusted sales should decline between 5% and 13% at constant exchange rates in 2026, a reversal from last year, when sales grew 10%.
